Neuroendocrine Tumors Emerging and Marketed Drugs Assessment (2023 Updates) | Clinical and Non-Clinical Trials Evaluation, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, about 50+ key pharma and biotech companies are working on 50+ pipeline drugs in the Neuroendocrine Tumors therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

“Neuroendocrine Tumors Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Neuroendocrine Tumors Market.

The Neuroendocrine Tumors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Neuroendocrine Tumors Pipeline Analysis
The report provides insights into:

– The report provides detailed insights about emerging therapies for the treatment of Neuroendocrine Tumors and the aggregate therapies developed by major pharma companies.
– It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuroendocrine Tumors Treatment.
– It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
– The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
– It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Neuroendocrine Tumors market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Delveinsight’s Report Covers Emerging Products Under Different Phases of Clinical Development Like –
– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage products (Phase I/II and Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates

Route of Administration
Neuroendocrine Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
– Oral
– Parenteral
– Intravitreal
– Subretinal
– Topical

Molecule Type
Products have been categorized under various Molecule types, such as
– Monoclonal Antibody
– Peptides
– Polymer
– Small molecule
– Gene therapy

Neuroendocrine Tumors Therapeutics Landscape

There are approx. 50+ key companies are developing therapies for Neuroendocrine Tumors. Currently, Hutchison MediPharma is leading the therapeutics market with its Neuroendocrine Tumors drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Neuroendocrine Tumors Therapeutics Market include:

– Amgen
– EpicentRx
– Genentech
– Hutchison MediPharma
– Ignyta
– Jiangsu Hengrui Medicine
– MedImmune
– Merck KGaA
– NanoValent Pharmaceuticals
– Pfizer
– Progenics Pharmaceuticals
– Takeda Oncology
– Vivace Therapeutics
And many others

Neuroendocrine Tumors Therapies covered in the report include:

– Axitinib: Pfizer
– Azedra: Progenics Pharmaceuticals
– Carfilzomib: Amgen
– Entrectinib: Ignyta
– RRx-001: EpicentRx
– Sulfatinib: Hutchison MediPharma
And many more

Explore More About the Emerging Drugs and Key Companies: Neuroendocrine Tumors Pipeline Development Activities

Table of Content (TOC)

1. Report Introduction
2. Executive Summary
3. Neuroendocrine Tumors Current Treatment Patterns
4. Neuroendocrine Tumors – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Neuroendocrine Tumors Late-Stage Products (Phase-III)
7. Neuroendocrine Tumors Mid-Stage Products (Phase-II)
8. Neuroendocrine Tumors Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Neuroendocrine Tumors Discontinued Products
13. Neuroendocrine Tumors Product Profiles
14. Key Companies in the Neuroendocrine Tumors Market
15. Key Products in the Neuroendocrine Tumors Therapeutics Segment
16. Dormant and Discontinued Products
17. Neuroendocrine Tumors Unmet Needs
18. Neuroendocrine Tumors Future Perspectives
19. Neuroendocrine Tumors Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Get a Detailed Assessment into the Ongoing Clinical and Regulatory Development Activities, at: Neuroendocrine Tumors Therapeutic Outlook

Contact Info:
Shruti Thakur
Manager (Marketing and Branding)
Email: info@delveinsight.com

Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving pharmaceutical market today @ Pharmaceutical Partner Identification Solutions

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.